TransMedics Group, Inc. (NASDAQ:TMDX) Given Average Rating of “Hold” by Brokerages

Shares of TransMedics Group, Inc. (NASDAQ:TMDX) have been assigned a consensus rating of “Hold” from the thirteen analysts that are presently covering the company, MarketBeat.com reports. Seven analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $134.50.

TMDX has been the topic of a number of analyst reports. Canaccord Genuity Group reiterated a “buy” rating and issued a $124.00 price target on shares of TransMedics Group in a research report on Tuesday. UBS Group restated a “hold” rating on shares of TransMedics Group in a research report on Tuesday, May 26th. Stifel Nicolaus lifted their price objective on TransMedics Group from $75.00 to $80.00 and gave the stock a “hold” rating in a research note on Thursday, June 18th. Wall Street Zen cut TransMedics Group from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of TransMedics Group in a research report on Tuesday, June 9th.

Insider Activity at TransMedics Group

In other news, Director Thomas J. Gunderson sold 9,624 shares of the stock in a transaction on Monday, June 15th. The shares were sold at an average price of $75.06, for a total transaction of $722,377.44. Following the completion of the sale, the director directly owned 16,642 shares in the company, valued at $1,249,148.52. This represents a 36.64% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 6.90% of the company’s stock.

Hedge Funds Weigh In On TransMedics Group

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Goldman Sachs Group Inc. grew its holdings in TransMedics Group by 50.1% during the 4th quarter. Goldman Sachs Group Inc. now owns 965,931 shares of the company’s stock worth $117,506,000 after acquiring an additional 322,353 shares during the period. Two Sigma Investments LP lifted its stake in shares of TransMedics Group by 54.2% in the 3rd quarter. Two Sigma Investments LP now owns 635,394 shares of the company’s stock valued at $71,291,000 after purchasing an additional 223,409 shares during the period. Wellington Management Group LLP boosted its position in shares of TransMedics Group by 100.5% during the 4th quarter. Wellington Management Group LLP now owns 433,321 shares of the company’s stock valued at $52,713,000 after purchasing an additional 217,180 shares in the last quarter. Price T Rowe Associates Inc. MD grew its stake in TransMedics Group by 43.2% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 569,970 shares of the company’s stock worth $69,338,000 after purchasing an additional 171,810 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in TransMedics Group by 11.9% during the third quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,069,492 shares of the company’s stock worth $119,997,000 after purchasing an additional 113,817 shares during the period. Institutional investors and hedge funds own 99.67% of the company’s stock.

TransMedics Group Price Performance

Shares of NASDAQ:TMDX opened at $67.85 on Friday. The firm has a market cap of $2.34 billion, a PE ratio of 15.42 and a beta of 1.89. The firm’s fifty day moving average is $76.75 and its 200-day moving average is $108.92. The company has a debt-to-equity ratio of 1.70, a quick ratio of 6.19 and a current ratio of 6.74. TransMedics Group has a 52 week low of $60.10 and a 52 week high of $156.00.

TransMedics Group (NASDAQ:TMDX) last posted its quarterly earnings data on Tuesday, May 5th. The company reported $0.30 earnings per share for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.32). The company had revenue of $173.93 million during the quarter, compared to analyst estimates of $174.44 million. TransMedics Group had a net margin of 27.04% and a return on equity of 22.38%. The business’s revenue for the quarter was up 21.2% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.70 earnings per share. Sell-side analysts predict that TransMedics Group will post 1.92 earnings per share for the current year.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.